🔗 Share this article

Ministers and senior MPs have issued warnings that the United Kingdom's recent agreements with the US administration are "fundamentally unstable." This follows revelations that a recently announced deal on medicines, which promises zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond limited headline terms published in government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "generational" achievement, exists as an "agreement in principle" without detailed provisions. Observers point out that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a singular success, while the American announcement dwells on the commitment for the NHS to pay higher prices for new medications.

"The danger exists that the UK government has agreed to terms to raise drug prices in return for little more than a assurance from President Trump," said David Henig, a trade expert. "We know he has a tendency for not honouring his word."

A Pattern of Unreliability

Worries have been amplified by Washington's recent decision to pause the high-value digital accord, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions agreed to for British farmers as part of an earlier tariff deal have not been formally ratified by the US, despite a imminent January deadline. "We have been informed that that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Privately, ministers have voiced worries that the government's deals with Washington are unstable and unpredictable. One minister described the series of agreements as "resting on shaky ground," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than Trump's temper tantrums is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Government figures have downplayed the chances of the US withdrawing from the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that instability is inherent in dealing with the Trump administration. However, they contend that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, issues have surfaced in enacting the initial US-UK accord. Promised access for British beef have not materialized, and the pledge to "eliminate duties on UK metals" has not been fulfilled, with tariffs fixed at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.